Solutions

We enable personalized cancer care

Our solutions provide physicians with precise cancer diagnostics, monitoring, and therapy-decision support.

Product Portfolio

  • Oncobit™ DxM

    Oncobit™ DxM is a targeted sequencing approach to assess FFPE tissue of advanced melanoma patients.

    Oncobit™ DxM captures:

    • mutations in all melanoma-relevant genes
    • melanoma-relevant gene rearrangements
    • copy number variants (CNV) in a genome-wide manner and chromosomal aneuploidies
    • total tumor mutational burden (TMB)
    • mutation signatures
    • HLA types
    • T-cell receptor (TCR) clonality

    All findings are annotated with a curated knowledge database of approved and off-label therapies and ongoing clinical trials relevant for the respective patient. Results, suggested therapies and trials are summarized in an automatically generated customized report, providing a precise diagnosis of the tumor as well as therapy decision support.

     

  • Oncobit™ LBM

    Oncobit™ LBM is a targeted sequencing approach to assess blood samples of advanced melanoma patients.

    Oncobit™ LBM captures:

    • mutations in 60 melanoma-relevant genes
    • copy number variants (CNV) in melanoma-relevant genes
    • HLA types

    All findings are annotated with a curated knowledge database to identify genomic alterations. Assessing circulating tumor-derived DNA (ctDNA) isolated from the blood of cancer patients, this method is minimally invasive and provides a comprehensive characterization of cancer and therapy resistance markers in the patient’s blood.

  • Oncobit™ PM

    Oncobit™ PM allows us to provide highly sensitive monitoring of specific molecular alterations with a short turnaround time. The number and type of alterations evaluated is customized for each patient.

    Similar to Oncobit™ LBM, Oncobit™ PM is a minimally invasive liquid biopsy assay. Oncobit PM represents a tool for personalized monitoring of cancer patients of all types of solid tumors.